CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

Detalles Bibliográficos
Autores principales: Yam, Clinton, Hung, Mien-Chie, Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188130/
https://www.ncbi.nlm.nih.gov/pubmed/30344934
http://dx.doi.org/10.18632/oncotarget.26134
_version_ 1783363163512635392
author Yam, Clinton
Hung, Mien-Chie
Hortobagyi, Gabriel N.
author_facet Yam, Clinton
Hung, Mien-Chie
Hortobagyi, Gabriel N.
author_sort Yam, Clinton
collection PubMed
description
format Online
Article
Text
id pubmed-6188130
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61881302018-10-21 CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line? Yam, Clinton Hung, Mien-Chie Hortobagyi, Gabriel N. Oncotarget Editorial Impact Journals LLC 2018-09-28 /pmc/articles/PMC6188130/ /pubmed/30344934 http://dx.doi.org/10.18632/oncotarget.26134 Text en Copyright: © 2018 Yam et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Yam, Clinton
Hung, Mien-Chie
Hortobagyi, Gabriel N.
CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title_full CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title_fullStr CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title_full_unstemmed CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title_short CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
title_sort cdk4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (her2)-negative metastatic breast cancer: are we at the finish line?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188130/
https://www.ncbi.nlm.nih.gov/pubmed/30344934
http://dx.doi.org/10.18632/oncotarget.26134
work_keys_str_mv AT yamclinton cdk46inhibitorsinhormonereceptorpositivehumanepidermalgrowthfactorreceptor2her2negativemetastaticbreastcancerareweatthefinishline
AT hungmienchie cdk46inhibitorsinhormonereceptorpositivehumanepidermalgrowthfactorreceptor2her2negativemetastaticbreastcancerareweatthefinishline
AT hortobagyigabrieln cdk46inhibitorsinhormonereceptorpositivehumanepidermalgrowthfactorreceptor2her2negativemetastaticbreastcancerareweatthefinishline

Ejemplares similares